Abstract: A pharmaceutical composition comprising: (a) an anticholinergic of formula 1 wherein X? is an anion with a single negative charge; (b) a corticosteroid; and (c) a betamimetic, wherein each component (a), (b), and (c) are optionally in the form of the solvates or hydrates thereof, processes for preparing them, and their use in the treatment of respiratory diseases.

Abstract: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.

Abstract: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

Abstract: The present invention relates to new thiazolyl-dihydro-indazoles of general formula (I) wherein the groups R1, R2 and R3 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical compositions.

Abstract: Fluorenecarboxylic acid esters of general formula 1 wherein X? and the groups A, R, R1, R2, R3, R3?, R4, and R4? have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof a medicaments.

Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics of the formula 1; wherein X?, R1 ? and Ar are defined as in claim 1, and a heterocyclic compound of the formula 2. Furthermore, the invention relates to processes for preparing them and their use in the treatment of respiratory complaints.

Abstract: The invention relates to a process for preparing new tiotropium salts, these new tiotropium salts as such, pharmaceutical formulations containing them and their use for preparing a medicament.

Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.

Abstract: The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, betamimetic 1, at least one anticholinergic 2 and at least one PDEIV-inhibitor 3, processes for preparing them and their use as pharmaceutical compositions.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergies and anti-TNF antibodies, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The present invention relates to new pharmaceutical compositions for inhalation containing one or more, preferably one anticholinergic 1 in combination with one or more pharmacologically acceptable acid addition salts of a compound of formula 2?, wherein the groups R1, R2, R3 and R4 may have the meanings given in the specification and in the claims, processes for preparing them and their use in the treatment of respiratory complaints.

Abstract: The present invention relates to new pharmaceutical compositions for inhalation containing one or more, preferably one anticholinergic 1 in combination with one or more betamimetics 2 and one or more steroids 3, processes for preparing them and their use in the treatment of respiratory complaints.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and TNF-alpha-antagonists, processes for preparing them and their use in the treatment of respiratory diseases.

Abstract: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.